Home
About +
Our Science +
Investors +
News +
Careers
Contact

Home
About
Our Science
Investors
News
Careers
Contact

Our Story
Meet the Team
FAQs

Inhaled IFN-β
Clinical Trials
Publications

Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Investor Calendar

Press Releases
Resources
Factsheets
TR-1/Options Press Releases

News

TR-1/Options Press Releases

Holding(s) in Company6th October 2022
Grant of Options6th July 2022
Holding(s) in Company15th June 2022
Exercise of Options and Total Voting Rights9th June 2022
Holding(s) in Company6th April 2022
Holding(s) in Company8th March 2022
Holding(s) in Company8th March 2022
Holding(s) in Company4th March 2022
Holding(s) in Company24th February 2022
Holding(s) in Company23rd February 2022
Holding(s) in Company4th February 2022
Director/PDMR Shareholding28th January 2022
Holding(s) in Company19th January 2022
Holding(s) in Company12th January 2022
Holding(s) in Company7th January 2022

Our Science
Interferon Beta
Investigating antiviral treatment in COVID-19
Investigating antiviral treatment in COPD
Investigating antiviral treatment in asthma
Relevant Publications

About
Home
Our Story
Team
FAQs
Careers
Contact

Investors
Investors Overview
Performance
Reports & Presentations
Investor News
Analysts
Investor Calendar

News
Press Releases
Factsheets
Resources

Cookie Policy Legal Privacy Policy

© Synairgen plc. All Rights ReservedRegistered in England and Wales No. 5233429 | Site by Ether